Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria

por De Mauleon, Adelaide, Ismail, Zahinoor, Rosenberg, Paul, Miller, David, Cantet, Christelle, O'Gorman, Cedric, Vellas, Bruno, Lyketsos, Constantine, Soto, Maria
Publicado 2021

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

por Correll, Christoph U., Davis, Robert E., Weingart, Michal, Saillard, Jelena, O’Gorman, Cedric, Kane, John M., Lieberman, Jeffrey A., Tamminga, Carol A., Mates, Sharon, Vanover, Kimberly E.
Publicado 2020

Esmethadone-HCl (REL-1017): a promising rapid antidepressant

por Fava, Maurizio, Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Bettini, Ezio, Comai, Stefano, Alimonti, Andrea, Bifari, Francesco, Pani, Luca, Folli, Franco, Guidetti, Clotilde, Furlan, Alberto, Sgrignani, Jacopo, Locatelli, Patrizia, Cavalli, Andrea, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Pappagallo, Marco, Manfredi, Paolo L.
Publicado 2023

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

por Shram, Megan J., Henningfield, Jack E., Apseloff, Glen, Gorodetzky, Charles W., De Martin, Sara, Vocci, Frank L., Sapienza, Frank L., Kosten, Thomas R., Huston, Jeff, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Folli, Franco, Mattarei, Andrea, Guidetti, Clotilde, Comai, Stefano, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Manfredi, Paolo L., Pappagallo, Marco
Publicado 2023